ID   MOLM-14
AC   CVCL_7916
SY   Molm-14; Molm 14; Molm14; MOLM14
DR   BTO; BTO:0005720
DR   Cell_Model_Passport; SIDM00436
DR   ChEMBL-Cells; CHEMBL3706571
DR   ChEMBL-Targets; CHEMBL3706570
DR   Cosmic; 787418
DR   Cosmic; 1150898
DR   Cosmic; 1281333
DR   DepMap; ACH-001574
DR   DSMZ; ACC-777
DR   DSMZCellDive; ACC-777
DR   GEO; GSM2037134
DR   GEO; GSM2037135
DR   GEO; GSM3145724
DR   JCRB; JCRB1812
DR   Lonza; 978
DR   PubChem_Cell_line; CVCL_7916
DR   Wikidata; Q54906323
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=9305600;
RX   PubMed=12529668;
RX   PubMed=21552520;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: 3-4 days (PubMed=9305600); ~50 hours (DSMZ=ACC-777).
CC   Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (PubMed=9305600).
CC   Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (PubMed=12529668).
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: H3K79me1 ChIP-seq epigenome analysis.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): COG; DepMap; DSMZ; JCRB
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 10,11
ST   D16S539: 10,11
ST   D18S51: 13,15
ST   D19S433: 12,14
ST   D21S11: 30,31
ST   D2S1338: 23,25
ST   D3S1358: 15
ST   D5S818: 10,11
ST   D7S820: 10,12
ST   D8S1179: 13,14
ST   FGA: 21,23
ST   Penta D: 9,12
ST   Penta E: 18,19
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_2119 ! MOLM-13
SX   Male
AG   20Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 24
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=9305600; DOI=10.1038/sj.leu.2400768;
RA   Matsuo Y., MacLeod R.A.F., Uphoff C.C., Drexler H.G., Nishizaki C.,
RA   Katayama Y., Kimura G., Fujii N., Omoto E., Harada M., Orita K.;
RT   "Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14)
RT   with interclonal phenotypic heterogeneity showing MLL-AF9 fusion
RT   resulting from an occult chromosome insertion,
RT   ins(11;9)(q23;p22p23).";
RL   Leukemia 11:1469-1477(1997).
//
RX   PubMed=12529668; DOI=10.1038/sj.leu.2402740;
RA   Quentmeier H., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "FLT3 mutations in acute myeloid leukemia cell lines.";
RL   Leukemia 17:120-124(2003).
//
RX   PubMed=21552520; DOI=10.1371/journal.pone.0019169;
RA   Gu T.-L., Nardone J., Wang Y., Loriaux M., Villen J., Beausoleil S.A.,
RA   Tucker M., Kornhauser J.M., Ren J.-M., MacNeill J., Gygi S.P.,
RA   Druker B.J., Heinrich M.C., Rush J., Polakiewicz R.D.;
RT   "Survey of activated FLT3 signaling in leukemia.";
RL   PLoS ONE 6:E19169-E19169(2011).
//